Antidepressant Efficacy and Cardiovascular Safety of Venlafaxine in Young Vs Old Patients with Comorbid Medical Disorders
- 1 December 1997
- journal article
- Published by SAGE Publications in The International Journal of Psychiatry in Medicine
- Vol. 27 (4) , 353-364
- https://doi.org/10.2190/udrd-99cb-t6kh-edkp
Abstract
Objective: To determine whether venlafaxine exerts a differential effect on blood pressure in young versus old depressed patients. Method: We compared thirty-four consecutive patients treated with 50–250 mg/day venlafaxine for major depressive disorder or another major mood disorder at our medical college's ambulatory neuropsychiatry program. We obtained baseline and follow-up blood pressure measurements. Each patient also received a baseline and final Clinical Global Impressions (CGI) score; global improvement was determined by consensus of two clinicians. Results: Sixteen nongeriatric patients (age, 13 to 56 years) were compared with eighteen elderly patients (age, 65 to 86 years). Most patients (88%) had serious medical comorbidities or histories. Despite a higher mean daily venlafaxine dosage for patients in the young group, no significant changes in systolic blood pressure were noted in either group. For the older group, we found a non-statistically significant 4.7 mm Hg mean increase in diastolic blood pressure. No patient became hypertensive. We also found a negative correlation between baseline diastolic blood pressure and change in diastolic blood pressure during treatment with venlafaxine. This inverse relationship was statistically significant in the older patients. Conclusions: Venlafaxine was not associated with significant, sustained changes in blood pressure in any patient receiving dosages of 50–250 mg/day. Minimal changes in diastolic blood pressure were no more likely to occur in older venlafaxine-treated patients than in younger ones. Higher baseline diastolic blood pressure in older patients, but not in younger ones, seemed to protect against diastolic adrenergic blood pressure effects of venlafaxine.Keywords
This publication has 6 references indexed in Scilit:
- The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V)Archives of internal medicine (1960), 1993
- Placebo-Controlled Trial of Venlafaxine for the Treatment of Major DepressionJournal of Clinical Psychopharmacology, 1991
- Biochemical, neurophysiological, and behavioral effects of Wy‐45,233 and other identified metabolites of the antidepressant venlafaxineDrug Development Research, 1991
- 2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activityJournal of Medicinal Chemistry, 1990
- Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivativeBiochemical Pharmacology, 1986